Novel extended in vitro-in vivo correlation model for the development of extended-release formulations for baclofen: From formulation composition to in vivo pharmacokinetics

被引:14
|
作者
Kim, Tae Hwan [1 ]
Bulitta, Jurgen B. [2 ]
Kim, Do-Hyung [3 ]
Shin, Soyoung [4 ]
Shin, Beom Soo [5 ]
机构
[1] Daegu Catholic Univ, Coll Pharm, Gyongsan 38430, Gyeongbuk, South Korea
[2] Univ Florida, Coll Pharm, Orlando, FL 32827 USA
[3] KNOTUS Co Ltd, Res Ctr, Guri 11910, Gyeonggi, South Korea
[4] Wonkwang Univ, Coll Pharm, 460 Iksan Daero, Iksan 54538, Jeonbuk, South Korea
[5] Sungkyunkwan Univ, Sch Pharm, Suwon, Gyeonggi, South Korea
基金
新加坡国家研究基金会;
关键词
Extended-release formulation; In vitro-in vivo correlation; Population pharmacokinetic model; Hydroxypropyl methylcellulose; Baclofen; INTESTINAL-ABSORPTION; POPULATION; TRANSPORT; MECHANISM; TABLETS; DESIGN; TIME;
D O I
10.1016/j.ijpharm.2018.12.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In vitro-in vivo correlation (IVIVC), a predictive mathematical model between the in vitro dissolution and the in vivo pharmacokinetics has been utilized for the development of new extended release (ER) formulations. The aim of the present study was to extend the IVIVC approach, which correlates among the formulation composition, the in vitro dissolution, and the plasma drug concentration, to predict plasma drug concentrations from a given composition of the formulation, and vice versa, using baclofen as a model drug. Baclofen ER tablets with different dissolution rates were prepared by varying the composition of hydroxypropyl methylcellulose (HPMC). First, the HPMC compositions and the corresponding in vitro dissolutions parameters were correlated, and then the in vitro dissolution parameters were correlated with the in vivo dissolution parameters extracted from the pharmacokinetic profiles of the baclofen ER formulations via population pharmacokinetic modeling. The final extended IVIVC model linked the composition of the formulation, the in vitro dissolution, and the in vivo plasma concentration profile and was successfully applied for the prediction of in vivo pharmacokinetics from the amount of HPMC in baclofen ER formulations. The present approach holds great promise for designing optimal compositions of ER formulations to present desired plasma concentration profile.
引用
收藏
页码:276 / 286
页数:11
相关论文
共 50 条
  • [41] In vitro in vivo relationship of oral extended-release dosage forms
    Liu, FY
    Sambol, NC
    Giannini, RP
    Liu, CY
    PHARMACEUTICAL RESEARCH, 1996, 13 (10) : 1501 - 1506
  • [42] Development and internal validation of an in vitro in vivo correlation for a hydrophilic metoprolol tartrate extended release tablet formulation
    Eddington, ND
    Marroum, P
    Uppoor, R
    Hussain, A
    Augsburger, L
    PHARMACEUTICAL RESEARCH, 1998, 15 (03) : 466 - 473
  • [43] ESTABLISHING IN VIVO TO IN VITRO CORRELATIONS FOR THE RATE OF RELEASE OF BEVACIZUMAB FROM EXTENDED RELEASE FORMULATIONS
    Owens, Gary
    Williams, Stuart
    Herlihy, Kevin
    Tully, Janet
    Verhoeven, Rozemarijn S.
    Navratil, Tomas
    Maynor, Benjamin
    Yerxa, Benjamin
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [44] Steady-state pharmacokinetics of a novel extended-release metformin formulation
    Timmins, P
    Donahue, S
    Meeker, J
    Marathe, P
    CLINICAL PHARMACOKINETICS, 2005, 44 (07) : 721 - 729
  • [45] Steady-State Pharmacokinetics of a Novel Extended-Release Metformin Formulation
    Peter Timmins
    Steve Donahue
    Jeff Meeker
    Punit Marathe
    Clinical Pharmacokinetics, 2005, 44 : 721 - 729
  • [46] Use of In Vitro-In Vivo Correlation to Predict the Pharmacokinetics of Several Products Containing a BCS Class 1 Drug in Extended Release Matrices
    Mirza, Tahseen
    Bykadi, Srikant A.
    Ellison, Christopher D.
    Yang, Yongsheng
    Davit, Barbara M.
    Khan, Mansoor A.
    PHARMACEUTICAL RESEARCH, 2013, 30 (01) : 179 - 190
  • [47] In vivo study of the effect of antacid on extended-release formulations of oxybutynin and tolterodine.
    Dmochowski, R
    Sathyan, G
    Ye, C
    Gupta, SK
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2002, 50 (04) : S39 - S39
  • [48] Engineered PLGA microspheres for extended-release of naltrexone: in vitro, in vivo, and IVIVR
    Sheikhlou, Maryam Ghareh
    Ravari, Nazanin Shabani
    Behrouzi, Milad
    Goodarzi, Navid
    Larijani, Roshana Saghafian
    Varshochian, Reyhaneh
    Dinarvand, Rassoul
    Rouini, Mohammad Reza
    PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2023, 28 (02) : 190 - 199
  • [49] LEVEL A IN VITRO-IN VIVO CORRELATION DEVELOPMENT AND VALIDATION FOR TRAMADOL HYDROCHLORIDE FORMULATIONS
    Cai, Yangping
    Li, Youshan
    Li, Shu
    Gao, Tian
    Zhang, Lu
    Yang, Zhe
    Fan, Zhengfu
    Bai, Chujie
    ACTA POLONIAE PHARMACEUTICA, 2016, 73 (05): : 1333 - 1338
  • [50] Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended-release microsphere formulation of azithromycin
    Chandra, Richa
    Liu, Ping
    Breen, Jeanne D.
    Fisher, Jeannine
    Xie, Charles
    LaBadie, Robert
    Benner, Rebecca J.
    Benincosa, Lisa J.
    Sharma, Amarnath
    CLINICAL PHARMACOKINETICS, 2007, 46 (03) : 247 - 259